Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.87EUR
18 Apr 2019
Change (% chg)

€-0.19 (-0.26%)
Prev Close
€73.06
Open
€72.50
Day's High
€73.83
Day's Low
€72.50
Volume
4,515,930
Avg. Vol
2,341,634
52-wk High
€80.44
52-wk Low
€63.25

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 29.30 32.55
EPS (TTM): 3.70 -- --
ROI: 5.69 14.23 13.83
ROE: 8.50 15.46 15.25

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

Apr 10 2019

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK, April 10 Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

Apr 10 2019

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

Mar 22 2019

UPDATE 1-FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

Mar 22 2019

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

Mar 22 2019

Exclusive: Sanofi says working on CEO succession plan

PARIS Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.

Mar 18 2019

BioNTech hires banks for IPO worth up to $800 million: sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

Mar 12 2019

UPDATE 2-BioNTech hires banks for IPO worth up to $800 million -sources

* IPO eyed in Q4 or early 2020-sources (Adds BioNTech comment)

Mar 12 2019

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

Earnings vs. Estimates